It really is all about numbers
The numbers I'm most interested in and the ones shareholders should pay the most attention to are the following:
* .16 launch point for FDA related news
* share count and option issuance since realease of trial "termination"
* number of days that BNC sat on the information to the time it was submitted to FDA
Given the action in this space, focus on anything else would seem useless and discussion of Endo or Valeant ( given the participants in the "Nasty Proxy Battle" ) would lead right back to the .16 SP
Concerned